Unlock instant, AI-driven research and patent intelligence for your innovation.

Difluorinated Compounds as Cystatins

A compound, suitable technology, applied in the direction of active ingredients of phosphorus compounds, biocides, anti-inflammatory agents, etc.

Inactive Publication Date: 2015-12-16
VIROBAY INC
View PDF28 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, aberrant activity of cysteine ​​proteases (e.g. due to increased expression or enhanced activation) can have pathological consequences

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Difluorinated Compounds as Cystatins
  • Difluorinated Compounds as Cystatins
  • Difluorinated Compounds as Cystatins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0122] In a particular aspect, the invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein:

[0123] R 1 is hydrogen or alkyl;

[0124] R 2 is hydrogen, alkyl, haloalkyl, carboxyalkyl, alkoxycarbonylalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, Heterocyclylalkyl, cyano or -alkylene-X-R 9 (Where X is -O-, -NR 10 -, -CONR 11 -, -S(O) n1 -, -NR 12 CO-, -CO- or -C(O)O-, wherein n1 is 0-2, and R 9 , R 10 , R 11 and R 12 independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl), where R 2 The aromatic ring or alicyclic ring in is optionally replaced by one, two or three R a substituted, the R a independently selected from alkyl, haloalkyl, alkoxy, hydroxy, haloalkoxy, halogen, carboxyl, alkoxycarbonyl, amino, monosubstituted amino, disubstituted amino, nitro, aryloxy, benzyloxy, Acyl or arylsulfonyl, and further wherein R ...

Embodiment 1

[0217] Synthesis Example 1-Scheme 1

[0218]

[0219] Scheme 1, Step 1: Synthesis of 1-aminocyclopropanenitrile hydrochloride (1-aminocyclopropanenitrile hydrochloride is commercially available)

[0220]

[0221] Benzophenone imine (25 g, 0.138 mol, Aldrich) and aminoacetonitrile hydrochloride (25 g, 0.270 mol, Lancaster) were dissolved in dichloromethane (1000 mL) in a 2 L Erlenmeyer flask at room temperature under nitrogen. The mixture was stirred for five days. The reaction mixture was filtered to remove precipitated ammonium chloride and the filtrate was evaporated to dryness in vacuo. The resulting residue was dissolved in ether (400 mL), washed with water (200 mL) and brine. After drying over magnesium sulfate, the solution was evaporated to give (benzhydrylamino)-acetonitrile (47.89 g).

[0222] Under nitrogen, an aqueous solution (91 mL) of sodium hydroxide (91 g, 2.275 mol) in a 2 L flask was cooled on ice, then, benzyltriethylammonium chloride (2.0 g, 0.008...

Embodiment 2

[0224] Synthetic Example 2: Scheme 2

[0225]

[0226] Scheme 2, Step 1: Synthesis of (S)-methyl 2-(benzyloxycarbonylamino)-4-chloro-4-oxobutanoate

[0227]

[0228] See Synth. Comm. 1993, 23(18):2511-2526. N-benzyloxycarbonyl-L-aspartic acid 2-methyl ester (5 g, 17.7 mmol) was dissolved in 30 ml of anhydrous THF, and 2 and stir at 0 °C. Thionyl chloride (10.5 g, 88.5 mmol, 5 equiv) was added to the solution by syringe at 0° C., and the solution was refluxed for one hour. The solvent was removed in vacuo and the product was crystallized from dichloromethane / hexanes to give methyl 2(S)-2-benzyloxycarbonylamino-3-chlorocarbonylpropionate.

[0229] 1 HNMR (400MHz, CDCl 3 )δ3.48(dd, 1H, J=18.5Hz, J=3.7Hz), 3.56(dd, 1H, J=18.5Hz, J=3.7Hz), 3.74(s, 3H), 4.58(m, 1H) , 5.10 (s, 2H), 5.72 (d, 1H), 7.30-7.35 (m, 5H) ppm.

[0230] Scheme 2, Step 2: (S)-2-(Benzyloxycarbonylamino)-4-oxo-5-phenylpentanoic acid methyl ester

[0231]

[0232] To a suspension of copper(I) brom...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to compounds which are inhibitors of cysteine ​​proteases, in particular cathepsins B, K, L, F and S, and are thus useful in the treatment of diseases mediated by these proteases. The invention also relates to pharmaceutical compositions comprising these compounds and processes for their preparation.

Description

Background technique [0001] The present invention relates to compounds which are inhibitors of cysteine ​​proteases, in particular cathepsins B, K, L, F and S, and are thus useful in the treatment of diseases mediated by these proteases. The invention also relates to pharmaceutical compositions comprising these compounds and processes for their preparation. [0002] Cysteine ​​proteases represent a class of peptidases characterized by the presence of a cysteine ​​residue in the catalytic site of the enzyme. Cysteine ​​proteases are involved in the normal degradation and processing of proteins. However, aberrant activity of cysteine ​​proteases (eg due to increased expression or enhanced activation) may have pathological consequences. In this regard, certain cysteine ​​proteases have been associated with various disease states including arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, periodontal disease, metachromatic encephalitis, L...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A01N57/00A61K31/66
CPCA61P9/10A61P11/06A61P17/02A61P17/06A61P19/02A61P21/04A61P25/00A61P25/04A61P29/00A61P37/00A61P43/00C07C255/46C07C2601/02
Inventor 约翰·O·林克克雷格·J·莫斯曼刘捷禹顺亨
Owner VIROBAY INC